MannKind (MNKD) Study result summary

Clinical program overview and study design

• Preclinical studies showed high lung concentrations and minimal systemic exposure, establishing a wide safety margin for nintedanib DPI before human trials.

• Phase 1a in healthy adults and Phase 1b (INFLO-1) in 27 IPF patients confirmed safety, tolerability, and predictable pharmacokinetics, with no serious adverse events or discontinuations.

• Phase 1b was a randomized, double-blind, placebo-controlled study using multiple ascending dose regimens over seven days at 10 U.S. sites.

• The global Phase 2 (INFLO-2) is enrolling up to 210 IPF patients aged 40–85, including both untreated and background-therapy patients, to assess safety, tolerability, and efficacy over nine months.

• Secondary endpoints in Phase 2 include lung function decline, disease progression, and patient-reported outcomes.

Key safety and tolerability findings

• No serious adverse events, GI issues, bronchospasm, or discontinuations were observed in IPF patients; no dose reductions required.

• Cough was the most common adverse event: 60% had no cough, 30% mild (grade 1), 10% moderate, all transient and mostly after first inhalation, with no severe cases or discontinuations.

• No difference in spirometry between active and placebo groups, supporting pulmonary safety in compromised lungs.

• Over 448–450 inhalations administered in IPF patients with no cough-related discontinuations.

• Safety profile consistent with prior Technosphere platform experience, with less than 3% discontinuation due to cough in approved products.

Pharmacokinetics and delivery platform

• Technosphere technology enables efficient, deep lung delivery, validated in over 50,000 patients and two FDA-approved DPI products.

• Nintedanib DPI achieved plasma Cmax values 6–8 times higher than nebulized nintedanib at comparable doses, indicating efficient lung delivery.

• High peak lung concentrations (Cmax) are believed to be more important for anti-fibrotic activity than total exposure (AUC).

• The dry powder inhaler format is well-accepted in pulmonary populations, including elderly and those with compromised lung function.

• Platform manufacturing complexity and extensive patent protection provide barriers to entry and long-term exclusivity, with patent estate extending to 2046+ and over 1,400 patents worldwide.